Inhibition of the gliadin-𝛼2 peptide can be a powerful step in creating a novel drug for CeD. Even though this project only inhibits one specific peptide, this process can easily be repeated for similar peptides. The research presented in this study will also show specific amino acid positions that are important for binding and sequences that repeat in other HLA-DQ2-binding peptides. In addition, this drug can be the basis for individual-based peptide therapies if extended to test an individual’s specific MHC-II complexes. This treatment does not rely on the use of enzymes, therefore opening the possibility to inhibit a larger range of peptides as they are not restricted to being degraded before entering the stomach and small intestine.
Project Notes